About Alseres Pharmaceuticals
Alseres Pharmaceuticals is a publicly listed company based in Auburndale (United States) founded in 1972. Therapeutic and diagnostic products for CNS disorders are developed. Alseres Pharmaceuticals has raised $4 million across 11 funding rounds from investors including Ingalls and Snyder. The company has 3 employees. Alseres Pharmaceuticals offers products and services including Altropane. Its focus areas include Life Sciences, Rare Diseases, Drugs and CNS. Its legal entity is Alseres Pharmaceuticals Inc. Its competitors include Harmony Biosciences, QurAlis and ImaginAb; 3 of its 3 listed competitors have raised funding.
Company details
Alseres Pharmaceuticals was established in 1972 in Auburndale, United States, with operations centered on pharmaceuticals for central nervous system disorders. Therapeutic and diagnostic products are developed, including Cethrin, a recombinant protein for nerve repair post-spinal cord injury. Preclinical efforts involve Inosine for spinal cord injury and stroke treatment, alongside a DAT blocker for Parkinsons disease. Altropane, an imaging agent, is advanced for diagnosing Parkinsons and dementia.
- Headquarters Auburndale, United States
- Employees 3
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website alseres.com
- Legal Name Alseres Pharmaceuticals Inc
- Total Equity Funding$4M (USD)
in 11 rounds
- Latest Funding Round$1M (USD), Post-IPO
Nov 2009
- Investors
- Employee Count3
Products & Services of Alseres Pharmaceuticals
Alseres Pharmaceuticals offers a comprehensive portfolio of products and services, including Altropane.
Molecular imaging agent for diagnosing Parkinson's disease and dementia.
Funding Insights of Alseres Pharmaceuticals
Alseres Pharmaceuticals has successfully raised a total of $4M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1 million completed in November 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4M
- Total Rounds 11
- Last Round Post-IPO — $1M
- First Round $4M
(Aug 2002)
- Investors Count 1
Latest 10 of 11 funding rounds of Alseres Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2009 | $1M | Post-IPO | – | – | – |
| Mar 2009 | $1M | Post-IPO | – | – | – |
| Feb 2009 | $200,000 | Post-IPO | – | – | – |
| Jan 2009 | $1M | Post-IPO | – | – | – |
| Jun 2008 | $5M | Post-IPO | – | – | – |
| Aug 2007 | $10M | Post-IPO | – | – | |
| Jun 2007 | $19M | Post-IPO | – | – | – |
| Sep 2005 | $12.78M | Post-IPO | – | – | – |
| Dec 2003 | $8M | Post-IPO | – | – | – |
| Mar 2003 | $10M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Alseres Pharmaceuticals
Alseres Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ingalls and Snyder.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provides customized investment advisory, portfolio management, and wealth planning services to clients. | 1924 | ingalls.net | New York, United States |
Investor details for Alseres Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Alseres Pharmaceuticals
4 dated milestones of Alseres Pharmaceuticals across 46 years, from founding to its latest funding, stage changes and deals.
- Founded Alseres Pharmaceuticals is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Post-IPO, of $1.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Alseres Pharmaceuticals
Alseres Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Harmony Biosciences, QurAlis and ImaginAb.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| harmonybiosciences.com | 2017 | Plymouth Meeting, United States | $345M | 246 | Developer of therapeutics for rare neurological diseases | |
| quralis.com | 2016 | Cambridge, United States | $155.45M | 38 | Drugs and CSF devices are developed for ALS treatment. | |
| imaginab.com | 2007 | Los Angeles, United States | $59.64M | 17 | ImaginAb is focused on developing advanced immuno-oncology imaging technologies. |
Detailed competitors of Alseres Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Imaging Diagnostics
3 companies that operate in the same segment as Alseres Pharmaceuticals (Imaging Diagnostics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Handheld ultrasound devices are developed for whole-body medical imaging. | 2011 | Guilford, Connecticut, United States | USD 350 M | USD 97.61 M | 464 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 | ||
Ultrasound images are analyzed via AI-based software provided by Exo. | 2015 | Redwood City, California, United States | USD 463.39 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alseres Pharmaceuticals
Complete news archive for Alseres Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alseres Pharmaceuticals
Alseres Pharmaceuticals was founded in 1972 and raised its 1st funding round 30 years after it was founded.
Alseres Pharmaceuticals is headquartered in Auburndale, United States. It is registered at Auburndale, Florida, United States.
Alseres Pharmaceuticals is a funded company, having raised a total of $4M across 11 funding rounds to date. The company's 1st funding round was a Post-IPO of $10M, raised on Aug 2002.
Alseres Pharmaceuticals has 3 employees.
Alseres Pharmaceuticals was established in 1972 in Auburndale, United States, with operations centered on pharmaceuticals for central nervous system disorders. Therapeutic and diagnostic products are developed, including Cethrin, a recombinant protein for nerve repair post-spinal cord injury. Preclinical efforts involve Inosine for spinal cord injury and stroke treatment, alongside a DAT blocker for Parkinsons disease. Altropane, an imaging agent, is advanced for diagnosing Parkinsons and dementia.
Alseres Pharmaceuticals's top competitors include Harmony Biosciences, ImaginAb and QurAlis.
Alseres Pharmaceuticals offers Altropane.
Alseres Pharmaceuticals has 1 investor. Key investors include Ingalls and Snyder.
Alseres Pharmaceuticals operates through Alseres Pharmaceuticals Inc.